Hunt G E, Atrens D M, Becker F T, Paxinos G
Eur J Pharmacol. 1978 Dec 15;53(1):1-8. doi: 10.1016/0014-2999(78)90261-3.
The alpha-adrenoceptor agonist clonidine (12.5--50.0 microgram/kg) produced a dose-dependent increase in the latency to initiate lateral hypothalamic stimulation. The insurmountable postsynaptic alpha-adrenoceptor antagonist phenoxybenzamine (0.2-0.8 mg/kg) had no effect on self-stimulation by itself, but potentiated the inhibitory effects of clonidine. The fact that the concurrent escape behavior to the intracranial stimulation was unchanged by either clonidine or the phenoxybenzamine-clonidine combination suggests that the inhibition is specific to the rewarding component of hypothalamic stimulation. Yohimbine (0.5--2.0 mg/kg) produced a dose-dependent increase in both response latencies. This lack of behavioral specificity may reflect yohimbine's wide range of pharmacological activity, Dexamphetamine (0.25--0.50 mg/kg) reversed clonidine's inhibition of self-stimulation reward in a specific and dose-dependent fashion. This reversal could be blocked by previous inhibition of catecholamine synthesis with alpha-methyl-p-tyrosine. These data support the concept that the alpha-adrenoceptors play a critical role in the modulation of hypothalamic self-stimulation reward. They further suggest that the inhibitory effects of clonidine on self-stimulation reward represent an agonist effect on presynaptic alpha-adrenoceptors.
α-肾上腺素能受体激动剂可乐定(12.5--50.0微克/千克)使开始下丘脑外侧刺激的潜伏期呈剂量依赖性增加。不可克服的突触后α-肾上腺素能受体拮抗剂酚苄明(0.2 - 0.8毫克/千克)自身对自我刺激无影响,但增强了可乐定的抑制作用。可乐定或酚苄明 - 可乐定组合对颅内刺激的同时逃避行为无改变,这一事实表明该抑制作用是下丘脑刺激奖赏成分所特有的。育亨宾(0.5--2.0毫克/千克)使两种反应潜伏期均呈剂量依赖性增加。这种行为缺乏特异性可能反映了育亨宾广泛的药理活性。右旋苯丙胺(0.25--0.50毫克/千克)以一种特异且剂量依赖性的方式逆转了可乐定对自我刺激奖赏的抑制作用。这种逆转可被先前用α-甲基 - 对 - 酪氨酸抑制儿茶酚胺合成所阻断。这些数据支持α-肾上腺素能受体在调节下丘脑自我刺激奖赏中起关键作用这一概念。它们进一步表明可乐定对自我刺激奖赏的抑制作用代表了对突触前α-肾上腺素能受体的激动剂作用。